Breaking news: Today, Alkermes was named as a Best Large Workplace in BioPharma? by Fortune Magazine! We are honored to receive this recognition, which is based on the results of a survey of #TeamAlkermes employees. Learn more about what makes Alkermes an employer of choice in the biotech space by checking out the article: https://lnkd.in/eU6ydQ5M
Alkermes
生物技术研究
Alkermes is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience.
关于我们
At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines
- 网站
-
https://www.alkermes.com/
Alkermes的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Dublin
- 类型
- 上市公司
- 创立
- 1987
- 领域
- Pharma、Pharmaceutical、Sales、Marketing、IT、CNS、Addiction、Information technology、Human Resources、Sales、District Sales、Regional Sales、Research & Development、R&D、Manufacturing、Medical Affairs、serious mental illness、biotech、addiction、narcolepsy、neuroscience、sleep disorders和biotech
地点
Alkermes员工
动态
-
According to SAMHSA’s 2023 National Survey on Drug Use and Health, more than 23% of people who reported using alcohol also reported binge drinking in the past month. If you’re struggling with drinking patterns and need support, you’re not alone. SAMHSA’s National Helpline is completely free, confidential, and available 24/7, 365 days a year to provide guidance and resources whenever you need them. Source: Substance Abuse and Mental Health Services Administration (SAMHSA) This post does not constitute or imply endorsement of Alkermes by the U.S. Government, including the Substance Abuse and Mental Health Services Administration.
-
-
At Alkermes, we leverage our more than 30 years of experience in our pursuit to make progress on behalf of people living with complex psychiatric and neurological disorders. Visit our website to learn more about what makes #TeamAlkermes special: www.alkermes.com
-
For the tens of thousands of people living with a sleep disorder including #narcolepsy, the physical and emotional burdens can take a heavy toll. Addressing these challenges and working towards a better understanding of this lived experience is central to our work in advancing sleep medicine. Watch this video to learn more.
-
This #WomensHistoryMonth and beyond, we celebrate the important contributions that women on #TeamAlkermes make to the success of our business. Thank you for all you do!
-
-
Did you know that as of 2021, only 1 in 5 U.S. adults with an #OpioidUseDisorder (OUD) received treatment? Despite widespread knowledge of the ongoing opioid use disorder epidemic and overdose crisis, many individuals may still lack awareness about the risk of opioid use and the availability of medical treatment for those who are eligible. The National Institutes of Health provides a comprehensive resource answering common questions about opioids and their effects. https://lnkd.in/ggCPtpQJ Source: National Institutes of Health This post does not constitute or imply endorsement of Alkermes by the U.S. Government, including the National Institute on Drug Abuse and National Institutes of Health.
-
-
Millions of Americans live with a mental health condition, meaning neighbors, coworkers, mere acquaintances or close loved ones may be dealing with a serious #mentalillness. When it comes to discussing mental health, there’s no one-size-fits-all approach. If you want to feel more confident in supporting someone who may be struggling, NAMI offers thoughtful guidance on starting these conversations, what to say (and what to avoid), and how to offer meaningful support. https://lnkd.in/guWhmdJb Source: NAMI
-
-
Yesterday, #TeamAlkermes put on their green for a St. Patrick’s Day celebration breakfast. Thanks to all who attended!
-
-
#SleepAwarenessWeek may be coming to an end, but our commitment to people living with sleep disorders continues! Visit our website to learn more about #narcolepsy and #idiopathichypersomnia. https://lnkd.in/g3nfQZMM
-
Today, #TeamAlkermes joins World Sleep Society and the global sleep community in celebrating #WorldSleepDay. While sleep health is a priority for all, Julie Lekstrom Himes, our SVP of Clinical Development, shines a light on the unique experiences of people living with idiopathic hypersomnia. https://lnkd.in/ga-uP4pf #ThisisIH
-